The inclusion of productivity value in the appraisal of health technologies is a subject of ongoing debate. In this blog, we discuss the potential impact of not considering productivity costs in the evaluation of vaccination programmes in the UK.
Berdud, Drummond and Towse (2020) propose a method for establishing a reasonable price for an orphan drug. Assuming prices for drugs are set according to incremental value, they propose adjustments to a payer’s ‘normal’ cost-effectiveness threshold (CET) for non-orphan drugs to ensure orphan drug developers achieve no more than the industry-wide rate of return. Adjustments are calculated for differences in R&D costs and population sizes.
In a recently published OHE Consulting Report, we report the long-term return on investment (ROI) per £1 spent on various vaccination programmes from the perspective of the UK government. In this blog, we discuss how discounting affects the estimated long-term value of vaccination and, thus, decision-makers’ investment decisions.
This year’s OHE lecture addressed the question: how should the world pay for a COVID-19 vaccine? The paper by Adrian Towse and Isobel Firth accompanying the lecture is now published. It builds on work undertaken with Kalipso Chalkidou, Rachel Silverman and Ganesh Ramakrishnan from the Center for...
